CFTR modulator triple therapy offers ‘breakthrough’ for 90% of CF patients

Positive early results with new generation CFTR corrector triple therapy are a “major breakthrough” for most cystic fibrosis patients, researchers say. Published in the NEJM, two parallel trials of triple therapy regimens of the small-molecule CFTR correctors VX-659 or VX445 in combination with tezacaftor–ivacaftor showed significant improvements for patients with the most common CFTR mutations. ...